Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

VANCOUVER and SAN DIEGO, March 13 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three and nine months ended January 31, 2008 and an update on its programs.

Jim DeMesa, M.D., President & CEO of MIGENIX stated, "With the conclusion of our third fiscal quarter and now being halfway through our fourth quarter, we are looking forward to the completion of enrollment in the Phase III Omigard registration trial for preventing catheter-related infections being conducted by our partner, Cadence Pharmaceuticals. With completion of this trial, we expect to enter into a very important time of clinical results over the next half of the year (with both Omigard and celgosivir, our Phase II hepatitis C drug candidate) followed by our potential entry into the regulatory approval process in 2009 with Omigard."

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study being conducted by our development and commercialization partner Cadence Pharmaceuticals is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. Cadence expects they will complete enrollment of the 1,850 patients planned for the trial in the second quarter of 2008, with results available in the second half of 2008. If the results of the trial are positive, Cadence expects to submit a New Drug Application ("NDA") for omiganan 1% gel in the first half of 2009. Under the terms of the agreement with Cadence, MIGENIX will receive up to US$27 million in development and commercialization milestone payments, upon the achievement of specified milestones, starting with the US and European regulatory submission process; and a double-digit royalty on net sales. MIGENIX has been and continues to be in discussions with p
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Researchers from the National Institute of Standards and Technology ... new way to introduce magnetic impurities in a semiconductor ... (STM). Detailed in a recent paper,* this technique will ... one at a time to learn about its electrical ...
(Date:12/4/2009)... Micro Nano Technology Products (ACAMP) hosts, ... 4 /PRNewswire/ - Today ACAMP hosted a health ... biomaterials and microfluidics can play a powerful role ... help promote health and improve the quality, cost ...
(Date:12/4/2009)... Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused ... of ethanol from non-food cellulosic wastes, has been ranked number ... "50 Hottest Companies in Bioenergy;" the company,s second consecutive year ... Ethanol among the top 20 bioenergy companies for two straight ...
(Date:12/3/2009)... MELVILLE, N.Y., Dec. 3 Nikon Corporation, an ... it has signed a licensing agreement with Harvard ... Stochastic Optical Reconstruction Microscopy (STORM) technology. Under the ... enabled microscopy systems and market them with the ...
Breaking Biology Technology:NIST researchers put a new spin on atomic musical chairs 2Alberta companies delivering new products to the health & medical marketplace 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3
... - David Cagigal knows the missing link in many ... after the implementation. , ,Cagigal, chief information technology officer ... miscalculate return on investment often neglect to factor in ... cost over the life of the application. , , ...
... Milwaukee, Wis. - To meet a growing bioinformatics challenge, ... from the Medical College of Wisconsin and Children's ... worldwide genetic tracking of human and animal influenza viruses. ... and health officials since the onset of the avian or ...
... potential infringers by licensing the patent rather than going ... a recent Federal Circuit Court ruling, that could become ... do this by sending out a carefully worded letter ... license and then negotiating the terms. These unsolicited licensing ...
Other Biology Technology:The business case for software applications 2The business case for software applications 3Medical College team creates website for tracking flu 2Medical College team creates website for tracking flu 3Patent licensing: For enforcing companies, the rules have changed 2Patent licensing: For enforcing companies, the rules have changed 3
(Date:12/4/2009)... to an analysis of statewide data taken from 1998-2001, ... year were more than three times likely to report ... their insurance status during pregnancy and delivery. , ... times more likely among mothers with Medicaid coverage, and ...
(Date:12/4/2009)... new mathematical model of heart cells, University of Iowa ... calmodulin kinase II (CaM kinase), disrupts the electrical activity ... also involved Columbia University, was published online Dec. 3 ... , "Recently, researchers have developed great interest in calmodulin ...
(Date:12/3/2009)... species can be likened to emptying a museum of its ... the trash, or replacing every local cuisine with McDonald,s burgers. ... not just make the world boring. New research now suggests ... some nasty disease. , "Habitat destruction and biodiversity loss,"driven by ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2U-Iowa study helps advance heart-related research 2Species down, disease up 2Species down, disease up 3Species down, disease up 4National Patients Rights Advocate Joins Truman Medical Centers as General Counsel 50009 1National Patients Rights Advocate Joins Truman Medical Centers as General Counsel 50009 2World Nanomedicine Market to Cross 24160 Billion by 2015 According to New Report by Global Industry Analysts Inc 12778 1World Nanomedicine Market to Cross 24160 Billion by 2015 According to New Report by Global Industry Analysts Inc 12778 2World Nanomedicine Market to Cross 24160 Billion by 2015 According to New Report by Global Industry Analysts Inc 12778 3iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 1iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 2iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 3iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 4
... This press release is not and,must not be, ... Japan, South Africa or the United States of America. ... jurisdictions or elsewhere,where their participation requires further offer documents, ... Swedish law. This is a,translation of the original Swedish ...
... researchers led by MIT has explained how contaminated batches ... traditional safety screens and kill dozens of patients recently ... led by Professor Ram Sasisekharan of MIT, identified the ... sulfate (OSCS). The researchers present their findings and offer ...
... oral health could become the first tool for dental ... disease treatments, say researchers at the University of Michigan. ... the bug that makes it is Porphyromonas gingivalis, an ... potential as a vaccine candidate, according to Charles Shelburne, ...
Other Biology News:Oberthur Technologies XPon Offer 2MIT-led teams unravel heparin death mystery 2MIT-led teams unravel heparin death mystery 3Presence of certain antibodies signals healthier teeth and gums 2
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: